# Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

> **NCT03825744** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 240 (actual)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Hetrombopag Olamine+Standard Therapy
- **DRUG:** Placebo+Standard Therapy

## Key facts

- **NCT ID:** NCT03825744
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-05
- **Primary completion:** 2024-07-03
- **Final completion:** 2024-07-03
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825744, "Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03825744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*